Literature DB >> 17117472

Paclitaxel-loaded composite fibers: microstructure and emulsion stability.

Amir Kraitzer1, Meital Zilberman.   

Abstract

New core/shell fiber structures loaded with paclitaxel were developed and studied. These composite fibers are ideal for forming thin, delicate, biomedically important structures for various applications. Possible applications include fiber-based endovascular stents that mechanically support blood vessels while delivering drugs for preventing restenosis directly to the blood vessel wall, or drug delivery systems for cancer treatment. The core/shell fiber structures were formed by "coating" nylon fibers with porous paclitaxel-containing poly(DL-lactic-co-glycolic acid) structures. Shell preparation ("coating") was performed by freeze-drying water in oil emulsions. The present study focused on the effects of the emulsion's formulation (composition) and processing conditions on the porous shell structure, which actually reflects the emulsion's stability and also the drug release profile from the fibers. In general, extremely porous "shell" structures were obtained with good adhesion to the core fiber. An increase in the emulsion's drug content and copolymer composition demonstrated a significant effect on pore size and distribution, because of enhanced emulsion instability, whereas the homogenization rate and duration had only a slight effect on the pores' microstructure. The thermodynamic parameters in the studied system are thus more important than the kinetic parameters in determining the emulsion's stability and the shell's porous structure. Copyright 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17117472     DOI: 10.1002/jbm.a.31068

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  1 in total

Review 1.  Electrohydrodynamics: A facile technique to fabricate drug delivery systems.

Authors:  Syandan Chakraborty; I-Chien Liao; Andrew Adler; Kam W Leong
Journal:  Adv Drug Deliv Rev       Date:  2009-08-03       Impact factor: 15.470

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.